A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
UroGen Pharma Ltd.
URGN
$2.0B
Mkt Cap
$40.97
-3.60%
UroGen Pharma Ltd. (URGN) has a 5-year average return on invested capital (ROIC) of -71.7%. This is below average and may indicate limited pricing power.
UroGen Pharma Ltd. (URGN) has a market capitalization of $2.0B. It is classified as a small-cap stock.
UroGen Pharma Ltd. (URGN) does not currently pay a regular dividend.
UroGen Pharma Ltd. (URGN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
UroGen Pharma Ltd. (URGN) reported annual revenue of $110 million in its most recent fiscal year, based on SEC EDGAR filings.
UroGen Pharma Ltd. (URGN) has a net profit margin of -139.8%. The company is currently unprofitable.
UroGen Pharma Ltd. (URGN) generated $-163 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our approved products Jelmyto (mitomycin) for pyelocalyceal solution and Zusduri (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer (“low-grade UTUC”) and recurrent low-grade intermediate risk non-muscle invasive bladder cancer (“low-grade intermediate risk NMIBC”), respectively.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 140M | 110M | 90M | 83M | 64M | - |
| Net Income | -133M | -153M | -127M | -102M | -110M | -111M |
| EPS | $-2.82 | $-3.19 | $-2.96 | $-3.55 | $-4.81 | $-4.96 |
| Free Cash Flow | -166M | -163M | -97M | -77M | -88M | -86M |
| ROIC | -33.7% | -49.2% | -173.5% | -29.0% | -46.0% | -60.9% |
| Gross Margin | 89.9% | 76.9% | 74.2% | 67.8% | 57.6% | - |
| Debt/Equity | 0.00 | -1.20 | -14.01 | -1.52 | -1.11 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -108M | -125M | -97M | -66M | -79M | -92M |
| Operating Margin | -77.0% | -113.7% | -107.1% | -79.2% | -122.8% | - |
| ROE | 0.0% | 268.6% | 342.8% | 132.3% | 271.2% | -211.6% |
| Shares Outstanding | 49M | 48M | 43M | 29M | 23M | 22M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 18M | N/A | N/A | N/A | N/A | N/A | 64M | 83M | 90M | 110M | 140M |
| Gross Margin | 26.7% | N/A | N/A | N/A | N/A | N/A | 57.6% | 67.8% | 74.2% | 76.9% | 89.9% |
| R&D | N/A | 19M | 37M | 49M | 47M | 48M | 53M | 46M | 57M | 67M | 63M |
| SG&A | 6.4M | 8.8M | 40M | 60M | 90M | 88M | 83M | 93M | 121M | 155M | 172M |
| EBIT | 798K | -20M | -77M | -109M | -127M | -92M | -79M | -66M | -97M | -125M | -108M |
| Op. Margin | 4.6% | N/A | N/A | N/A | N/A | N/A | -122.8% | -79.2% | -107.1% | -113.7% | -77.0% |
| Net Income | -4.4M | -21M | -76M | -105M | -128M | -111M | -110M | -102M | -127M | -153M | -133M |
| Net Margin | -25.1% | N/A | N/A | N/A | N/A | N/A | -170.6% | -123.6% | -140.4% | -139.8% | -94.8% |
| Non-Recurring | 0 | 0 | -100K | 0 | 0 | 0 | 870K | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||
| ROIC | 4.9% | -49.1% | -95.4% | -77.8% | -92.9% | -60.9% | -46.0% | -29.0% | -173.5% | -49.2% | -33.7% |
| ROE | -27.1% | -49.1% | -95.4% | -77.8% | -92.9% | -211.6% | 271.2% | 132.3% | 342.8% | 268.6% | 0.0% |
| ROA | -37.1% | -42.2% | -84.5% | -68.7% | -79.2% | -91.7% | -86.0% | -65.1% | -54.7% | -63.1% | -52.5% |
| Cash Flow | |||||||||||
| Op. Cash Flow | 4.2M | -9.6M | -37M | -71M | -106M | -85M | -88M | -76M | -97M | -162M | -166M |
| Free Cash Flow | 3.5M | -9.8M | -38M | -71M | -107M | -86M | -88M | -77M | -97M | -163M | -166M |
| Owner Earnings | 2.0M | -16M | -68M | -101M | -134M | -109M | -99M | -87M | -110M | -175M | -180M |
| CapEx | 695K | 271K | 560K | 325K | 1.2M | 752K | 254K | 194K | 295K | 289K | 299K |
| Maint. CapEx | 200K | 200K | 400K | 300K | 416K | 831K | 924K | 802K | 329K | 307K | 310K |
| Growth CapEx | 495K | 71K | 160K | 25K | 799K | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 200K | 200K | 400K | 300K | 416K | 831K | 924K | 802K | 329K | 307K | 310K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.0M | 6.3M | 31M | 30M | 28M | 23M | 11M | 9.3M | 13M | 12M | 14M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | N/A | N/A | N/A | -208M | -141M | -111M | -841K | -52M | -159M | -33M | 41M |
| Cash & Equiv. | 21M | 37M | 101M | 50M | 53M | 44M | 55M | 95M | 172M | 111M | 150M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | 0 | 98M | 99M | 122M | 122M | 190M |
| Debt/Equity | 0.41 | 0.10 | 0.15 | 0.02 | 0.03 | 0.05 | -1.11 | -1.52 | -14.01 | -1.20 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | -9.4 | -4.5 | -7.7 | -8.1 | -8.1 |
| Equity | 16M | 69M | 90M | 180M | 96M | 8.4M | -89M | -65M | -8.8M | -105M | -124M |
| Total Assets | 23M | 76M | 104M | 202M | 122M | 120M | 136M | 178M | 286M | 200M | 254M |
| Total Liabilities | 6.7M | 7.0M | 13M | 22M | 26M | 111M | 225M | 244M | 295M | 306M | 378M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -27M | -47M | -123M | -228M | -357M | -467M | -577M | -679M | -806M | -960M | -983M |
| Working Capital | 19M | 67M | 89M | 129M | 94M | 92M | 105M | 138M | 230M | 140M | 187M |
| Current Assets | 22M | 74M | 102M | 149M | 116M | 114M | 129M | 169M | 276M | 186M | 237M |
| Current Liabilities | 3.1M | 7.0M | 13M | 19M | 21M | 22M | 24M | 31M | 46M | 46M | 51M |
| Per Share Data | |||||||||||
| EPS | -1.91 | -2.14 | -4.80 | -5.12 | -5.90 | -4.96 | -4.81 | -3.55 | -2.96 | -3.19 | -2.82 |
| Owner EPS | 0.88 | -1.65 | -4.34 | -4.93 | -6.17 | -4.87 | -4.34 | -3.00 | -2.57 | -3.63 | -3.69 |
| Book Value | 7.07 | 7.04 | 5.72 | 8.78 | 4.42 | 0.38 | -3.92 | -2.26 | -0.21 | -2.19 | -2.55 |
| Cash Flow/Share | 1.82 | -0.98 | -2.37 | -3.46 | -4.86 | -3.80 | -3.84 | -2.65 | -2.26 | -3.38 | -2.73 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.3M | 9.7M | 15.8M | 20.5M | 21.8M | 22.3M | 22.8M | 28.8M | 42.9M | 48.1M | 48.7M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -14.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 5.4 | 7.7 | 3.8 | 4.0 | 25.5 | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | 2.9 | 4.3 | 6.8 | 6.6 | 14.2 |
| FCF Yield | N/A | -2.6% | -5.5% | -10.5% | -27.6% | -39.9% | -47.1% | -17.7% | -21.0% | -14.7% | -8.3% |
| Market Cap | N/A | 372M | 693M | 680M | 389M | 214M | 186M | 434M | 461M | 1.1B | 2.0B |
| Avg. Price | N/A | 25.96 | 49.89 | 34.68 | 23.88 | 17.37 | 8.13 | 12.28 | 14.36 | 14.95 | 40.97 |
| Year-End Price | N/A | 38.25 | 43.96 | 33.13 | 17.85 | 9.60 | 8.16 | 15.06 | 10.76 | 23.03 | 40.97 |
UroGen Pharma Ltd. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 69.1%.
UroGen Pharma Ltd. (URGN) reported earnings per share (EPS) of $-3.19 in its most recent fiscal year.
UroGen Pharma Ltd. (URGN) has a return on equity (ROE) of 268.6%. This indicates the company generates strong returns for shareholders.
UroGen Pharma Ltd. (URGN) has a 5-year average gross margin of 69.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 10 years of financial data for UroGen Pharma Ltd. (URGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
UroGen Pharma Ltd. (URGN) has a book value per share of $-2.19, based on its most recent annual SEC filing.